CA3123393A1 - Deutetrabenazine for the treatment of dyskinesia in cerebral palsy - Google Patents
Deutetrabenazine for the treatment of dyskinesia in cerebral palsy Download PDFInfo
- Publication number
- CA3123393A1 CA3123393A1 CA3123393A CA3123393A CA3123393A1 CA 3123393 A1 CA3123393 A1 CA 3123393A1 CA 3123393 A CA3123393 A CA 3123393A CA 3123393 A CA3123393 A CA 3123393A CA 3123393 A1 CA3123393 A1 CA 3123393A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- baseline
- deutetrabenazine
- score
- study
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779232P | 2018-12-13 | 2018-12-13 | |
| US62/779,232 | 2018-12-13 | ||
| US201962801450P | 2019-02-05 | 2019-02-05 | |
| US62/801,450 | 2019-02-05 | ||
| PCT/US2019/066150 WO2020123900A1 (en) | 2018-12-13 | 2019-12-13 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3123393A1 true CA3123393A1 (en) | 2020-06-18 |
Family
ID=69173404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3123393A Pending CA3123393A1 (en) | 2018-12-13 | 2019-12-13 | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11324732B2 (https=) |
| EP (1) | EP3893876A1 (https=) |
| JP (1) | JP2022519007A (https=) |
| KR (1) | KR20210114946A (https=) |
| CN (1) | CN113395966A (https=) |
| AU (1) | AU2019395250A1 (https=) |
| BR (1) | BR112021011386A2 (https=) |
| CA (1) | CA3123393A1 (https=) |
| CL (1) | CL2021001554A1 (https=) |
| IL (1) | IL283920A (https=) |
| MX (1) | MX2021007063A (https=) |
| SG (1) | SG11202106344SA (https=) |
| TW (1) | TWI784220B (https=) |
| WO (1) | WO2020123900A1 (https=) |
| ZA (1) | ZA202104786B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI784220B (zh) * | 2018-12-13 | 2022-11-21 | 美商奧斯拜客斯製藥有限公司 | 腦性麻痺運動障礙之治療方法 |
| IL307678A (en) * | 2021-04-15 | 2023-12-01 | Neurocrine Biosciences Inc | Methods of administering certain VMAT2 inhibitors |
| JP2024514873A (ja) * | 2021-04-15 | 2024-04-03 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法 |
| WO2024090922A1 (ko) | 2022-10-24 | 2024-05-02 | 주식회사 디자인셀 | 줄기세포 배양액 및 상기로부터 분리된 세포외소포를 유효성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010044981A2 (en) * | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| AU2015200243B2 (en) * | 2009-06-24 | 2016-09-29 | Egalet Ltd | Controlled release formulations |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| HRP20221106T1 (hr) * | 2015-03-06 | 2022-11-25 | Auspex Pharmaceuticals, Inc. | Postupci liječenja abnormalnih nevoljnih poremećaja pokreta |
| UA127052C2 (uk) * | 2017-03-15 | 2023-03-29 | Оспекс Фармасьютікалс, Інк. | Аналоги деутетрабеназину, їхнє отримання та застосування |
| TWI784220B (zh) * | 2018-12-13 | 2022-11-21 | 美商奧斯拜客斯製藥有限公司 | 腦性麻痺運動障礙之治療方法 |
-
2019
- 2019-12-13 TW TW108145866A patent/TWI784220B/zh active
- 2019-12-13 AU AU2019395250A patent/AU2019395250A1/en not_active Abandoned
- 2019-12-13 CA CA3123393A patent/CA3123393A1/en active Pending
- 2019-12-13 WO PCT/US2019/066150 patent/WO2020123900A1/en not_active Ceased
- 2019-12-13 BR BR112021011386-0A patent/BR112021011386A2/pt not_active Application Discontinuation
- 2019-12-13 KR KR1020217021438A patent/KR20210114946A/ko not_active Abandoned
- 2019-12-13 JP JP2021534126A patent/JP2022519007A/ja active Pending
- 2019-12-13 SG SG11202106344SA patent/SG11202106344SA/en unknown
- 2019-12-13 US US16/713,917 patent/US11324732B2/en active Active
- 2019-12-13 MX MX2021007063A patent/MX2021007063A/es unknown
- 2019-12-13 EP EP19839001.5A patent/EP3893876A1/en not_active Withdrawn
- 2019-12-13 CN CN201980089635.4A patent/CN113395966A/zh active Pending
-
2021
- 2021-06-11 CL CL2021001554A patent/CL2021001554A1/es unknown
- 2021-06-12 IL IL283920A patent/IL283920A/en unknown
- 2021-07-08 ZA ZA2021/04786A patent/ZA202104786B/en unknown
-
2022
- 2022-04-12 US US17/718,441 patent/US20220409597A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,197 patent/US20240082225A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021001554A1 (es) | 2022-02-11 |
| US20240082225A1 (en) | 2024-03-14 |
| TW202034917A (zh) | 2020-10-01 |
| SG11202106344SA (en) | 2021-07-29 |
| US20220409597A1 (en) | 2022-12-29 |
| BR112021011386A2 (pt) | 2021-08-31 |
| US20200188371A1 (en) | 2020-06-18 |
| TWI784220B (zh) | 2022-11-21 |
| KR20210114946A (ko) | 2021-09-24 |
| IL283920A (en) | 2021-07-29 |
| MX2021007063A (es) | 2021-12-10 |
| ZA202104786B (en) | 2023-12-20 |
| CN113395966A (zh) | 2021-09-14 |
| JP2022519007A (ja) | 2022-03-18 |
| EP3893876A1 (en) | 2021-10-20 |
| AU2019395250A1 (en) | 2021-07-29 |
| WO2020123900A1 (en) | 2020-06-18 |
| US11324732B2 (en) | 2022-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2879631T3 (es) | Pridopidina para el tratamiento de la enfermedad de Huntington | |
| JP2025036702A (ja) | 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法 | |
| US20240082225A1 (en) | Methods for the treatment of dyskinesia in cerebral palsy | |
| US20230321007A1 (en) | Pharmacokinetics of nmda receptor antagonists | |
| US20110319384A1 (en) | Pharmaceutical Compositions | |
| US20210308115A1 (en) | Pridopidine for treating huntington's disease | |
| CN113825510A (zh) | 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法 | |
| JP2024517937A (ja) | Ｎｍｄａ受容体拮抗薬の副作用の低減 | |
| CN118555956A (zh) | 用于治疗难治性抑郁症的赛洛西宾和辅助血清素再摄取抑制剂 | |
| WO2024145288A2 (en) | Methods of administering r-ketamine | |
| CN119654149A (zh) | 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法 | |
| EA044015B1 (ru) | Дейтетрабеназин для лечения дискинезии при церебральном параличе | |
| US20250375417A1 (en) | Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1) | |
| HK40060751A (en) | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine | |
| EP4618973A1 (en) | Methods of switching neuropsychiatric medications using ulotaront | |
| CN121013719A (zh) | 治疗特发性震颤的方法 | |
| EA046262B1 (ru) | Уменьшение побочных эффектов антагонистов n-метил-d-аспартата (nmda) | |
| BA | A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa | |
| Chan et al. | Basics of Psychopharmacological Management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231106 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250129 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250529 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260226 |